Vancouver, WA – CytoDyn, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it is currently accepting only 155 more candidates across the country for its Phase 2b/3 registrational trial in